Company Reports

Cochlear's fiscal 2026 underlying net profit fell 22% to AUD 322 million, the top of the range it cut to in April. Fiscal 2027 guidance of AUD 330 million-AUD 350 million represents about 5% growth on last year at the midpoint. Shares rose 8%.

Cochlear is the market leader in cochlear implants with a consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-market adults as the next primary focus and emerging-market children after that.

We transfer coverage of Cochlear, the leading cochlear implant manufacturer, with around 60% global market share. Developed markets are 80% of revenue, where it largely targets adults and seniors facing hearing loss.

Cochlear is the market leader in cochlear implants with a consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-market adults as the next primary focus and emerging-market children after that.

Cochlear significantly cut its full-year underlying net profit after tax guidance by 23% at the midpoint to AUD 290 million-AUD 330 million from the implied guidance in February 2026 of AUD 405 million. The downgrade was mostly due to higher costs expected and soft market growth. Shares fell 41%.

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Cochlear's interim 2026 underlying net profit after tax was down 10%. Sales fell 2% due to contracting delays for the new Nucleus Nexa implant in developed markets. Inefficient manufacturing and distribution for Nexa and a shift to lower-margin emerging markets dragged further. Shares fell 19%.

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Shares in Cochlear have fallen roughly 20% since July. Fiscal 2025 underlying net profit after tax grew just 1% because of a sales mix shift to lower-margin emerging markets. In October, the firm reiterated fiscal 2026 underlying NPAT guidance of 8% growth at the midpoint.

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Cochlear's fiscal 2025 underlying net profit after tax grew just 1% to AUD 392 million, with revenue up 3% and margins contracting due to a sales mix shift to lower-margin emerging markets. Fiscal 2026 underlying NPAT guidance implies 8% growth at the midpoint.

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Cochlear downgraded fiscal 2025 NPAT guidance by 6% at the midpoint to AUD 390 million-AUD 400 million. Services revenue declined more than expected and cochlear implant sales in developed markets have slowed. The firm is also launching the Nucleus Nexa Cochlear Implant system in June 2025.

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Wide-moat Cochlear's interim fiscal 2025 sales of AUD 1.2 billion and underlying net profit after tax of AUD 206 million, up 6% and 1% in constant currency, respectively, tracked slightly behind our full-year forecasts. While sales of cochlear and acoustic implants grew strongly on solid adult referral rates, services revenue moderated more than we expected, down 12% in constant currency. This was largely due to cost-of-living pressures in the US causing higher rates of cancellations, and the Nucleus 8 maturing in its product life cycle after a successful launch in 2023.

Shares in narrow-moat CSL and wide-moat Cochlear are trading roughly flat since US President-elect Donald Trump named avowed vaccine skeptic Robert F. Kennedy Jr. as his pick to lead the US Health Department on Nov. 14, 2024. Similarly, the news does not materially change our long-term views, and we maintain our AUD 310 fair value estimate for CSL and AUD 225 for Cochlear.

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Wide-moat Cochlear reported fiscal 2024 sales of AUD 2.3 billion and underlying net profit after tax, or NPAT, of AUD 387 million, up 12% and 15% in constant currency, respectively, 2% below our expectations on average. While implant units sold in developed markets grew strongly on increasing adult referral rates, units sold in emerging markets declined in the second half. This was largely due to the 2024 elections in India affecting the timing of tenders. In addition, second-half services revenue moderated more than we expected, down 5% in constant currency.

The Australian Competition & Consumer Commission has approved wide-moat Cochlear’s acquisition of Oticon’s cochlear implants business. We had expected this to proceed and maintain our AUD 220 fair value and earnings estimates.